Aeterna Zentaris’ German subsidiary transferred manufacturing rights and granted a manufacturing license for Cetrotide® to Merck Serono. The deal is expected to be finalized on or about October 1, 2013. At that point Aeterna Zentaris would receive a one-time payment of approximately $3.2 million and certain other payments.
In addition, Aeterna Zentaris entered into a transitional services agreement with Merck KGaA under which the company will, during a 36-month period, provide various transition services to assist Merck KGaA in assuming responsibility for the manufacturing of Cetrotide in consideration for the payment of a monthly fee to the company.
Cetrotide (cetrorelix acetate for injection) is used to regulate hormone responses in women undergoing infertility treatment.
GlobalData estimates that the value of the women’s infertility market will reach $1.61 billion by 2017, up from $1.42 billion in 2009.